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Borderline ovarian tumors (BOTs) need to be differentiated from ovarian carcinomas
due to different presentation and management. Absent stromal invasion is the key
differentiating feature on histopathological examination. Considering the degree of

Keywords

aggressiveness between epithelial ovarian carcinoma and benign ovarian neoplasms like
cystadenoma, borderline neoplasms are closer to benign ovarian neoplasms as regards

•

BOTs

•

MPSC

•

APST

the clinical behavior. Surgery with intention of removal of all visible tumors is the most
important pillar in treatment. Patients treated conservatively with fertility sparing surgery
or laparoscopic surgery has low recurrence rate, making both options worth considering.
Overall prognosis of these tumors is good with survival rate more than 90% at 10 years
in early stage borderline tumors. However, small percentage of patients with borderline
neoplasms may show more aggressive form of the disease, and trials have been made to
figure out the histological correlates that might predict for worse outcome. There is no
added advantage of postoperative adjuvant chemotherapy or radiation in any stage
especially with non-invasive component. Follow up is done by observation of the patient
and any further intervention is kept reserved for recurrent disease.
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Borderline ovarian tumors are characterized by

involvment. [2] In 1961, FIGO (The International

certain criteria that includes having atypical

Federation of Gynecology and Obstetrics)

epithelial proliferation with lack of stromal

described BOTs as a unique category due to the

[1]

BOT’s name was

fact that they have a low malignant inclination

firstly suggested by Taylor in 1929 as “semi-

and so The World Health Organization (WHO)

malignant” disease because BOTs have certain

named them “borderline” in 1973. At the present

characteristics that combine both being benign

time, BOTs are described by three names:

and malignant ovarian tumors, but the prognosis

borderline tumor, tumor of low malignant

of the patient who has BOT is better than any

potential, and atypical proliferative tumor

other ovarian tumor even with peritoneal

(Figure1) [3].

invasion histologically.

Figure 1: Ovarian tumour classification (WHO) [3]

Borderline ovarian tumors are different from

or conservative surgery and according to the

epithelial ovarian cancer in that they have low

staging, decide the best option of treatment and

incidence, is not particularly associated with

acquire a precise prognosis [4].

abnormalities in BRCA genes, rate of survival is

Incidence:

higher due to early stage diagnosis, and

Borderline ovarian tumors make up about 20%

associated with infertility which occurs on many

of the ovarian tumors. In author’s experience, the

occasions. One of the most important things to

patients with BOTs who were treated over the

take care of in these patients is the protection of

last 21 months made up only 9.3% [5].

fertility as it most commonly occurs in young
women. The way to manage the treatment of
these tumors is still not yet defined and
debatable. The most recent researches draw a

Epidemiology:
The risk of BOT is increased by primary
infertility

and

nulliparity.

However,

line under the staging of these tumors by radical

https://mmj.mans.edu.eg/home/vol50/iss4/6
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breastfeeding, multiple pregnancies and oral
[6]

contraceptives are protective .

the risk of BOT when the patients take fertility
drugs followed by ovarian stimulation and

There are several hypotheses that have been

multiple ovarian punctures. According to the

outlined to support the reproductive risk factors.

hormonal hypothesis, estrogen and androgen

If repeated microtrauma occurred to ovarian

stimulates

surface during ovulation, it would eventually

progesterone acts as a protective factor. Another

lead to ovarian malignancy. On the other hand,

hypothesis denotes the interrelation between

another hypothesis mentions that malignancy

endometriosis and external carcinogens (as talc,

can happen after ovarian exporsure to increased

asbestos) in tumorigenesis especially clear cell

levels of gonadotropins. A few case control

and endometrioid type of BOTs (Figure 2) [7].

neoplasms

growth,

meanwhile

studies observed a two to four folds increase in

Figure 2: Hypotheses for development of borderline ovarian neoplasms [7].

Women who underwent in-vitro fertilization
(IVF) have enhanced risk of being diagnosed

borderline ovarian tumors were observed with
unusual levels of CA 125[9].

with borderline ovarian neoplasms. In addition,
women with BRCA mutations are hardly ever

Histopathology and Classification

seen with borderline ovarian tumors. Almost 10-

BOTs are classified based on the FIGO

35% of patients with BOT are infertile [8]. Serum

classification, which is almost similar to that of

markers are not helpful in diagnosing borderline

ovarian tumors. However, the majority of BOTs

ovarian neoplasms, except for advanced-stage

(60-70%) are diagnosed at stage 1 in contrast to

BOT. 83% of patients with advanced stage

ovarian tumors which only 25% of them are

disease and 40% of women with stage 1

diagnosed at stage 1. It is very rare to find BOTs

Published by Mansoura Medical Journal, 2023
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in late stages as 2 or 3, moreover exceptional at
[10]

invasion. The majority of borderline epithelial

In terms of histopathology, there are

tumors, like that of carcinomas, are serous

important features that have to be distinguished

tumors (53-65%). Mucinous BOT makes up

for BOT differentiation from benign cyst

between 32% and 42% of the total. The rest of

adenoma; these features are: existence of

BOTs types also includes endometrial tumors,

epithelial budding, multilayered epithelium,

clear cell tumors, Brenner’s tumors which make

enhanced mitotic activity, presence of nuclear

up less than 5%(Table 1)[11].

stage 4.

atypia[10].
In addition, the difference between BOT and
ovarian cancer is the absence of stromal
Table 1. Histological classification of borderline ovarian neoplasms.[11]
Type
Serous

Subtype WHO
Typical subtype
(90%)
Micropapillary
subtype (10%)

Blaustein

Other histological characteristics

Benign group, APSTs
Low grade malignant group:
Noninvasive MPSC
Low grade malignant group: APST
with invasive peritoneal implants

a) Usual type (eosinophilic type), which
b)

are cells with ample eosinophilic
cytoplasm
structures are identical in appearance
to invasive lowgrade micropapillary
serous carcinoma

Mucinous

Intestinal subtype Intestinal subtype (85%)
(85%)
Mullerian subtype Mullerian subtype (15%)
(15%)

Mucinous
borderline
tumor
with
microinvasion
and/or
intraepithelial
carcinoma
Microinvasion
and/or
intraepithelial
carcinoma as well as peritoneal implants, may
be present.

Endometriod

Adenomatos
appearance
Glandular/papilla
ry appearance

Endometrioid
borderline
tumor
with
microinvasion
and/
or
intraepithelial
carcinoma and/or extraovarian implants

Clear cell

Clear-cell borderline tumor with microinvasion
and/or intraepithelial carcinoma

Brenner
(transitional cell)

Resembling low-grade papillary urothelial
carcinoma of the urinary tract

BOTs can be further classified into several
categories, because they had several different

Serous BOT
WHO studies of ovarian tumors showed that

biological potentials. (Table 1) [12].

there are two types of serous borderline ovarian

The first type is typical pattern, which makes up

tumors: typical serous BOTs (90%) and

90% of the cases and have unilocular cystic

micropapillary

(5-10%).

mass with fine interior septa. (Figure 3)[13] . The

However, recent studies showed that serous

second type is micropapillary pattern found in

patters

of

https://mmj.mans.edu.eg/home/vol50/iss4/6
DOI: 10.21608/mjmu.2021.83176.1026
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10% of the cases and presenting specific

more invasive form, greater prevalence of

histological features. They have a worse

bilateralilty and upstaging after performing

prognosis as compared to typical pattern serous

restaging surgery [13].

BOTs because of increased rate of recurrence,

Figure 3: Low power view of a serous borderline ovarian tumor with numerous papillae, broad and edematous, with
complex, hierarchical branching (a) small papillae which appear detached from larger papillae with epithelial
proliferation (b) immunostaining demonstrating a diffusely and strongly positive reaction (c) [13].

Mucinous BOT

probably the appendix

[14]

. There are two sub

They appear to be larger in size compared with

types: Intestinal (85-90%): The most common

serous BOT and on gross examination they have

type and the majority is unilateral. However,

either unilocular or multilocular cyst with fine

primary intestinal cancer must be excluded in

interior septa and intramural nodules.(Figure 4)

presence

Peritoneal implants are not common (15%) and

Endocervical or müllerian (10-15%): they are

if they occur, pseudomyxoma peritonei must be

bilateral in 40% of cases and 20-30% of which

excluded. It is considered a differentiated as

are related to pelvic endometriosis, ipsilateral

peritoneal involvement of mucinous carcinoma

endometriomas or BOT of mixed histology

is originally from digestive origin, most

(seromucinous) [14].

of

bilateral

involvement.

[14]

Figure 4: High power view of a mucinous borderline ovarian tumor that shows papillae with scanty stromal cores
(a) lined by atypical stratified cells (b) and immunostaining that shows a diffusely and strongly positive reaction (c)
[14]
.

Published by Mansoura Medical Journal, 2023
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gene (50%), PTEN gene (20%) as well as micro

Pathogenesis:
There are two pathways which have been
suggested in pathogenesis of serous BOTs. The

satellite instability gene (up to 50%) [17].
Clinical Presentation:

first one is “low grade” pathway which includes

The majority of patients having BOT are

BRAF and KRAS mutations, where the serous

asymptomatic. It can be accidently discovered

ovarian cyst adenomas advance to serous BOTs

during pelvic examination as a pelvic mass, or

which will further be low grade serous epithelial

ovarian masses can be detected by screening for

cancer through a continuation of histologic

abdominal ultrasound. About the majority

precursor lesions. Yet only 2% of the serous

percent as 50-60% present with symptoms as

borderline ovarian tumors become carcinomas

abdominal

through the “low grade” pathway [15]. The second

swelling, irregular GUT motions, persistent

pathway is the “high grade” pathway which

tiredness, or weight loss. A minority of women

includes p53 gene mutations. There is no known
precursor, but most of the serous ovarian cancers
belong to the high-grade pathway [15].
Serous

borderline

ovarian

tumors

are

distinguished via activation of specific tumor
suppressor genes (SERPINA 5 and dual
specificity phosphatase 4) which hinder the
breaking down of the extracellular matrix, an
important incident in pathogenesis of invasive
growth.

[16]

Mucinous tumorigenesis includes a

pattern of malignant modifications from benign
mucinous neoplasms to carcinomas. There are
three classes of bas oncogenes which are K, N
and H. Mucinous BOTs had an increased rate of
KRAS mutations when compared to that of
muchness cyst adenoma, yet less than that of
mutinous carcinoma. It is not evident if BRCA1
and BRCA2 multiplies the chances of BOT

[16]

.

Endometrioid borderline ovarian neoplasms, in
contrast to serous and mucinous BOTs, are
identified by mutations including beta catenin

https://mmj.mans.edu.eg/home/vol50/iss4/6
DOI: 10.21608/mjmu.2021.83176.1026

pain

or

discomfort,

abdominal

(10%) have irregular uterine bleeding [18].
Diagnosis:
BOTs are hard to discover clinically until they
have very large size or in very advanced late
stages. Pelvic ultrasound can help detect the
ovarian masses, but it is not specific or sensitive,
so it is not such a helpful screening tool to use
for all patients (Figure 5). BOTs appear on
ultrasound typically as: unilocular cyst with
solid papillary projections (defined as any
projection with a height ≥3 mm) arising from the
inner wall and with a positive ovarian crescent
sign (Figures 6,7). In contrast to ovarian
carcinoma, BOTs do not present with ascites.
Serum CA 125 also is not specific or accurate
for diagnosing or following up with a patient
having borderline ovarian tumor. In a systematic
review, 53.8% of patients had negative CA125
concentrations [19].
The diagnosis of BOTs is done intra-operative
through frozen section examination of the tumor
or post-operatively. The criteria for diagnosing

6
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include absence of stromal invasion and two or

papillary projections, cellular pleomorphism,

more of the following criteria: epithelial

nuclear atypia as well as mitotic activity [19].

proliferation, stratified epithelium, microscopic

Figure 5: Serous borderline tumor (transvaginal scan). Multilocular-solid tumor with papillae, rather smooth inner
cyst wall, and regular septa and anechoic intracystic fluid [19].

Figure 6: Unilocular cyst with solid papillary projections in BOT [19].

Figure 7: Papillary projections in BOT [19].

Prognosis:
Usually BOTs have good prognosis, with the

architecture (for serous BOTs) and is linked to
invasive

implants

in

45%

of

patients,

[20]

exception of 10% recurrence rate and 20-30%

microinvasion

malignancy risk. The characteristics that appear

residual disease, pathologically advanced stage,

to be associated with poor prognosis are:

and extra-ovarian invasive implants in addition

Transformation of borderline tumors to invasive

to pathologically advanced stage are major

disease which is dependent on: cell type, stage,

predictor for both recurrences and poorer

implant type (for serous BOTs), micropapillary

survival. Histological type: Serous tumors have

Published by Mansoura Medical Journal, 2023
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poor prognosis in contrast to non-serous tumors,

Therapeutic approaches:

which have excellent prognosis irrespective of

The main therapy for borderline ovarian

the presence or absence of intraepithelial

neoplasms is surgical resection. There has been

[21]

. Genetic

a shift in management from doing radical

factors: Presence of aneuploid DNA content

surgery to a more conservative approach, as

have a poor prognosis regarding recurrence and

BOT has a tendency to influence younger

survival. Both BRAF and KRAS mutations in

females [22].

carcinoma and/or microinvasion

serous and only KRAS mutations in mucinous
tumor have been linked to progression and
[21]

As the diagnosis of BOT is determined preoperatively,

intra-operative

frozen

section

. Type of surgery and

examination is important to treat a suspicious

surgical approach affect the prognosis by having

ovarian mass to customize the extent of

an impact on residual disease and in presence of

resection. However, it must be noted that frozen

residual tumor load have poor impact on

section has a limited accuracy, it certainly

worse prognosis

recurrence rate

[20]

depends

.

on

the

experience

of

the

Conservative treatment in form of preservation

histopathologist. BOT is under-diagnosed in

of uterus and one ovary, is associated with

intra-operative frozen section in 31% of patients.

increased disease recurrence in the remaining

A sub-diagnosis differentiates a BOT from

ovary, although it does not lead to poorer

malignant tumor in 25% of patients, which

survival as most of the recurrences in the

means that the patient has to get through another

remaining ovary are noninvasive type especially

surgery and the final histopathological results

for early stages. Unilateral oophorectomy rather

appear to be malignant ovarian tumor [22].

than

A- Radical surgery

cystectomy

is

preferred

when

the

contralateral ovary is normal in younger age

The standard radical surgery should be

patients where fertility is desired so as to avoid

performed to women who has completed their

recurrence. Conservative laparoscopic approach

reproductive wishes, which is total hysterectomy

is associated with twice more recurrence rate

with

than laparotomy, but overall survival rate is not

inframesocolic

reduced [21].

macroscopically suspicious lesion and peritoneal

bilateral

salpingooophorectomy,

omentectomy,

resection

of

Postoperative adjuvant treatment

washing, including exploration of the abdominal

(chemotherapy, radiotherapy) is not

cavity. Nodal involvement does not particularly

recommended as it leads to increased treatment

affect the survival of the patients, in spite of the

related morbidity and mortality rather than the

fact that it is associated with an increased rate of

disease itself [21].

recurrence,

so

lymphadenectomy

https://mmj.mans.edu.eg/home/vol50/iss4/6
DOI: 10.21608/mjmu.2021.83176.1026

pelvic
is

not

and
an

paraaortic
important
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requirement as it does not have a prognostic

should be done to patients who have abnormal

value in BOT. Involvement of the lymph nodes

gross appearance of the appendix especially with

does

the mucinous type to rule out synchronous or

not

reduce

survival;

neither

does

lymphadenectomy enhance it. Appendectomy

primitive appendiceal neoplasm. (Figure 8) [23].

Figure 8: Surgical specimen of an ovary. a Papillary serous ovarian cystadenoma. b Bilateral mucinous ovarian
cystadenoma [23].

increased risk of recurrence. As a result, the
gynecologic oncologist has to consider the

B- Conservative surgery
Since the majority of the patients with BOT are

advantages and disadvantages of a fertility

in their childbearing age, fertility preservation is

sparing approach in females having BOTs and

a critical concern in deciding treatment of

counsel the female on the importance of the

borderline ovarian tumors. Fertility sparing

long-term follow up [24].

surgical technique, which preserves uterus and at

There are two types of conservative surgery;

least part of one ovary, may be the ideal

the first one is unilateral salpingo-oopherectomy

treatment especially for patients with FIGO

(USO) and the second is unilateral ovarian

stage 1 and age less than 40 years. Therefore, if

cystectomy with or without contralateral ovarian

tumor is limited to the ovary in patients,

cystectomy (ultra-conservative surgery). The

unilateral salpingo-oopherectomy or ovarian

higher rate of relapse is associated with

cystectomy with complete surgical staging is

cystectomy compared to USO [24].

the

For serous tumors, several factors should be

contralateral ovary should be avoided, because it

considered as the age of the patient, persistence

can result in peritoneal adhesions or unwanted

of normal ovarian tissue on ultrasonography or

damage to the ovarian reserve. Biopsy should be

MRI, and antra follicle count. For mutinous

done only in patients with bilateral ovarian

tumors, although the lesions are unilateral, they

involvement,

or

are often accompanied with invasive lesions, so

salpingo-

the conservative management by cystectomy is

recommended.

bilateral

However,

cystectomy

ovaries,

or

biopsy

in

of

unilateral

unilateral

oophrectomy with contralateral cystectomy.

not necessary [25].

Although fertility sparing treatments for BOTs

Bilateral salpingo-oopherectomy is preferred in

may allow future pregnancies, it also carries and

patients with massive BOT, as preservation of

Published by Mansoura Medical Journal, 2023
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any part of the ovary is not practical. The uterus

laparoscopic surgery for BOTs is still indefinite,

could be preserved for oocyte donation or

yet there are advantages such less adhesion risk,

transfer of frozen embryos obtained before the

less morbidity, shorter hospital stay, shorter

bilateral salpingo-oophorectomy [25].

post-operative recovery and better cosmoses.

Complete resection should be done for serous

However, there are a few disadvantages as it

BOTs, as the aggressive nature and poor

carries a higher risk of rupture to the cyst

prognosis of invasive peritoneal implants may

capsule and incomplete staging occur more

increase the risk to progression to invasive

commonly with laparoscopy than by laparotomy

carcinoma. Mucinous tumors are more probably

[27]

to turn out into invasive carcinoma

[25]

.

.

Re-staging Surgery
In

BOTs

patients

who

undergone

Completion of surgery after fertility-sparing

oophorectomy or cystectomy should have no

approach

any additional staging surgery, but regular

The recurrence rates of BOTs are higher after

transvaginal ultrasonography follow up is

fertility sparing surgery than following radical

important. Studies noting the similarity and

surgery; nevertheless, after the desire for

differences between complete surgical staging

conception is completed, whether there must be

(CSS) with incomplete surgical staging in

a second surgical look to remove the uterus and

women with BOTs showed that restaging must

contra-lateral ovaries is still controversial.

be individualized and be supported by doctor’s

Studies showerd that there is no difference in

opinion and woman’s wish. They came to an

means of survival rates after surgery for BOTs

agreement that restaging surgery may be

[26]

. It was suggested that radical surgery should

be done for serous BOTs in case of disease
recurrence. Whereas, surgery completion should
be done for mucinous BOTs because many
mucinous BOTs relapse as invasive ovarian
carcinomas. So, in these young women, the
psychological impact on them is very important
and must not be ignored, hence an accurate
preoperative fertility counseling should be done
[26]

.

Laparoscopy for BOTs
During this era, benign ovarian masses are

suggested if: [28]
(1) There are histological criteria implying
invasive recurrence (peritoneal implant or
micropapillary pattern).
(2) Peritoneum has not been clearly reported as
“normal” or if there was no systematic
exploration within the initial operation.
(3) If macroscopic peritoneal implants have been
found intraoperatively.
(4) If gross lesion exists following initial
operation.

often dealt with via laparoscopy. The role of

https://mmj.mans.edu.eg/home/vol50/iss4/6
DOI: 10.21608/mjmu.2021.83176.1026

10

Abodabesh et al.: Recent updates in Management of Borderline Ovarian Tumors
227

Borderline Ovarian Tumors

(5) If the patient is less likely to return for

Management of recurrence

normal follow-up. Complete surgical staging

The site of recurrence is most common in the

was reduced to a decreased recurrence risk,

remaining ovary. The only situation where

although a non-significant correlation with

recurrent disease could affect the prognosis is

survival was detected [28].

when the character of the recurrent disease is

Generally, BOT women must be closely

invasive. Cytoreductive surgery should be

followed up after the conservative surgery,

performed when an extra ovarian borderline or

therefore the advantages and disadvantages

invasive relapse occurs. Cytoreductive surgery is

should be assessed by gynecological oncologist.

the best as it acts as an independent prognostic

Balancing the treatment with the oncological

factor and will determine the overall survival. A

safety in mind, remains a challenging task over

study revealed a mortality rate in women with

the last decades [28].

optimal debulking of 12%, compared with 60%

Follow up

of women who were suboptimally debulked [30].

Follow-up should be done every three months

Conclusion

during first two years, every six months between

BOTs differ from the epithelial ovarian

2 - 5 years and then annually. Clinical evaluation

malignancies in their excellent prognosis,

must

125

curability with surgery, and being seen in

concentrations. A detailed follow-up of patients

relatively young ages. Thus, fertility sparing,

who were treated conservatively, with an

and

attention to the remaining ovary, is a must. MRI

currently

should be done if local recurrence is suspected

diagnosis of BOTs may be challenging as the

while a contrast enhanced CT is useful if there is

clinical and ultrasonographic features might

be

added

to

TVS

and

suspicion of extrapelvic recurrence

CA

[29]

.

conservative
highly

surgical

approaches

endorsed.

are

Preoperative

overlap with invasive carcinomas and sometimes

Adjuvant chemotherapy (cisplatin-based) is not

with benign adnexal masses. Frozen section is

needed in stage 1 BOTs and debatable in

necessary for the intraoperative diagnosis,

advanced-stage

of

despite the fact that the diagnostic value of

hormonotherapy in the treatment of BOTs is still

frozen section is not as elevated as in invasive

controversial, even though >90% of BOTs are

ovarian carcinomas. Conservative approach

estrogen receptor positive. Any contraceptive

might improve the recurrence rate without

methods including hormonal contraceptives and

worsening the general survival. The definitive

hormone replacement therapy can be used safely

role of laparoscopic surgery with its pros and

in the patients with a diagnosis of BOT [29].

cons within the treatment of BOTs has to be

BOTs.

The

role

further studied.

Published by Mansoura Medical Journal, 2023

11

Mansoura Medical Journal, Vol. 50 [2023], Iss. 4, Art. 6
228

ElBayoumi et al.,

References:

Technology in cancer research & treatment;

1. Prat J.(2017).Pathology of borderline and

19:1533033820946423.

invasive cancers. Best practice & research

8. Sun Y, Xu J, et al. (2020). The Diagnosis,

Clinical obstetrics & gynaecology; 41:15-

Treatment,

30.

Pathology of Borderline Ovarian Tumors:

2. Carcangiu ML, Kurman RJ, et al. (2014).

Prognosis

and

Molecular

Current Status and Perspectives. Cancer

WHO classification of tumours of female

Management and Research; 12:3651-9.

reproductive organs: International Agency

9. Gica N, Mustata L, et al. (2020).
Management

for Research on Cancer.

of

Borderline

Ovarian

3. Karlsen NMS, Karlsen MA, et al.(2016).

Tumors: Series of Case Report and Review

Relapse and disease specific survival in

of the Literature. Indian Journal of Surgery;

1143

12:1-8.

Danish

borderline

women

ovarian

diagnosed
tumours

with

(BOT).

Ovarian Seromucinous Borderline Tumors

Gynecologic oncology;142(1):50-3.
4. Colombo N, Sessa C, et al. (2019). ESMO–
ESGO

consensus

10. Hada T, Miyamoto M, et al. (2020).

conference

Are Histologically Different from Mucinous
Borderline Tumors. In Vivo;34(3):1341-6.

cancer:

11. Genestie C, Auguste A, et al. (2020).

pathology and molecular biology, early and

Histological classification of mucinous

advanced stages, borderline tumours and

ovarian

recurrent

reproducibility, clinical relevance, and role

recommendations

on

disease.

ovarian

Annals

of

5. Tumor—An BO, Gyn O. (2019). Borderline
Tumor—An

inter-observer

of genetic biomarkers. Virchows Archiv;

Oncology;30(5):672-705.

Ovarian

tumors:

Overview

3:1-7.

and

12. Zheng R, Heller DS. (2019). Borderline

Evidence Based Management. Pan;2(1):30-

Brenner tumor: a review of the literature.

6.

Archives

6. Nayyar N, Lakhwani P, et al. (2017).
Management

of

Borderline

of

pathology

&

laboratory

medicine;143(10):1278-80.

Ovarian

13.Hauptmann S, Friedrich K, et al. (2017).

Tumors—Still a Gray Zone. Indian Journal

Ovarian borderline tumors in the 2014

of Surgical Oncology ;8(4):607-14.

WHO classification: evolving concepts and

7. Zhang Y, Li C, Luo S, et al. (2020).
Retrospective Study of the Epidemiology,

diagnostic

criteria.

Virchows

archiv;470(2):125-42.

Pathology, and Therapeutic Management in

14. Chen RF, Tao X, et al. (2020). Mucinous

Patients With Mucinous Ovarian Tumors.

borderline ovarian tumors with and without
Intraepithelial Carcinoma: Differences in

https://mmj.mans.edu.eg/home/vol50/iss4/6
DOI: 10.21608/mjmu.2021.83176.1026

12

Abodabesh et al.: Recent updates in Management of Borderline Ovarian Tumors
229

Borderline Ovarian Tumors

clinicopathologic
results.

Journal

features
of

and

fertility

Obstetrics

21. Jiao X, Hu J, Zhu L. (2017). Prognostic

and

factors

Gynaecology Research;46(4):646-53.

for

recurrence

preserving

surgery

after

in

fertility-

patients

with

15. Lu J, Pi S, et al. (2019). Value of

borderline ovarian tumors: a systematic

normalized apparent diffusion coefficients

review and meta-analysis of observational

in differentiating between borderline and

studies.

malignant

Gynecologic Cancer ;27(9).

epithelial

ovarian

tumors.

European journal of radiology; 118:44-50.

International

Journal

of

22. Gica N, Mustata L, et al. (2020).

16. Seong SJ, Kim DH, et al. (2015).

Management

of

Borderline

Ovarian

Controversies in borderline ovarian tumors.

Tumors: Series of Case Report and Review

Journal of gynecologic oncology;26(4):343-

of

9.

Surgery:1-8.

17. Gungorduk K, Asicioglu O, et al. (2017).

the

Literature.

Indian

Journal

of

23. Zhao J, Liu C, et al. (2018). Short-term

The impact of surgical staging on the

outcomes

prognosis of mucinous borderline tumors of

laparoscopic fertility-sparing surgery for

the ovaries: a multicenter study. Anticancer

borderline ovarian tumors: a single-institute

research;37(10):5609-16.

experience.

18. Sozen H, Vatansever D, et al. (2019).

and

pregnancy

International

rate

after

Journal

of

Gynecologic Cancer ;28(2).

Clinicopathological analysis of borderline

24. Maramai M, Barra F, et al. (2020).

ovarian tumours and risk factors related to

Borderline ovarian tumours: management in

recurrence: experience of single institution.

the

Journal

ecancermedicalscience;14.

of

Obstetrics

and

Gynaecology;39(2):253-8.

era

of

fertility-sparing

surgery.

25. Helpman L, Yaniv A, et al. (2017). Fertility

19. Shah JS, Mackelvie M, et al. (2019).

preservation in women with borderline

Accuracy of intraoperative frozen section

ovarian tumors–how does it impact disease

diagnosis of borderline ovarian tumors by

outcome? A cohort study. Acta Obstetricia

hospital type. Journal of minimally invasive

et

gynecology.;26(1):87-93.

;96(11):1300-6.

20. Jia SZ, Xiang Y, et al. (2020). Oncofertility

26.

Gynecologica

Scandinavica

Sleiman Z, Karaman E, et al. (2019).

outcomes after fertility-sparing treatment of

Fertility

bilateral serous borderline ovarian tumors:

gynecological diseases: current approaches

results of a large retrospective study.

and

Human Reproduction;35(2):328-39.

Reproduction & Infertility;20(4):201.

Published by Mansoura Medical Journal, 2023

future

preservation

perspectives.

in

benign

Journal

of

13

Mansoura Medical Journal, Vol. 50 [2023], Iss. 4, Art. 6
230

ElBayoumi et al.,

27. Morgan RJ, Alvarez RD, et al. (2013).
Ovarian cancer, version 2.2013. Journal of
the

National

Comprehensive

Cancer

Network;11(10):1199-209.
28. Abascal-Saiz A, Sotillo-Mallo L, et al.
(2014). Management of borderline ovarian
tumours: a comprehensive review of the
literature. ecancermedicalscience ;8.
29. Prat J. (2014). The results of conservative
(fertility-sparing) treatment in borderline
ovarian tumors vary depending on age and
histological type. European Society for
Medical Oncology.
30. Gouy S, Maria S, et al. (2020). Results
After Conservative Surgery of Stage II/III
Serous Borderline Ovarian Tumors. Annals
of Surgical Oncology:1-8.

https://mmj.mans.edu.eg/home/vol50/iss4/6
DOI: 10.21608/mjmu.2021.83176.1026

14

